ストックスクリーナーアプリを入手
28.51
7.58%
2.01
アフターアワーズ：
28.62
0.11
+0.39%
前日終値:
$26.50
開ける：
$26.515
24時間の取引高:
6.59M
Relative Volume:
3.14
時価総額：
$5.27B
収益：
$1.03B
当期純損益:
$-297.43M
株価収益率:
-17.65
EPS:
-1.615
ネットキャッシュフロー:
$-261.39M
1週間 パフォーマンス:
+21.01%
1か月 パフォーマンス:
+48.96%
6か月 パフォーマンス:
-10.93%
1年 パフォーマンス:
-14.64%
1日の値動き範囲:
$26.44
$30.41
1週間の範囲:
$22.42
$30.41
52週間の値動き範囲:
$16.24
$44.90
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Compare LEGN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
28.51 | 4.90B | 1.03B | -297.43M | -261.39M | -1.615 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-12 | ダウングレード | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | ダウングレード | TD Cowen | Buy → Hold |
| 2026-01-07 | 開始されました | Oppenheimer | Outperform |
| 2025-10-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-06-17 | 開始されました | Truist | Buy |
| 2024-05-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-05-23 | 開始されました | Deutsche Bank | Buy |
| 2024-04-17 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | Raymond James | Outperform |
| 2023-12-19 | 開始されました | Scotiabank | Sector Perform |
| 2023-11-06 | 開始されました | Goldman | Buy |
| 2023-05-25 | 開始されました | William Blair | Mkt Perform |
| 2023-05-22 | 開始されました | Daiwa Securities | Buy |
| 2023-03-29 | 開始されました | H.C. Wainwright | Buy |
| 2023-03-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-11-02 | 開始されました | Evercore ISI | Outperform |
| 2022-11-01 | 開始されました | Cowen | Outperform |
| 2022-10-31 | 開始されました | Guggenheim | Neutral |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-03-15 | 開始されました | Barclays | Overweight |
| 2022-01-31 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | 開始されました | Piper Sandler | Overweight |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2020-07-01 | 開始されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Legend Biotech Corp Adr (LEGN) 最新ニュース
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Legend Biotech (LEGN) moves 18.4% higher: Will this strength last? - MSN
Legend Biotech Corporation Sponsored ADR $LEGN Stock Holdings Lowered by Matthews International Capital Management LLC - MarketBeat
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last? - Yahoo Finance
H.C. Wainwright reiterates Legend Biotech stock rating on M&A activity By Investing.com - Investing.com South Africa
Raymond James reiterates Legend Biotech stock rating on strong trial data - Investing.com
H.C. Wainwright reiterates Legend Biotech stock rating on M&A activity - Investing.com
Why Legend Biotech Stock Crushed the Market on Monday - The Motley Fool
RBC Capital reiterates Legend Biotech stock rating on pharma interest By Investing.com - Investing.com India
Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday - Benzinga
H.C. Wainwright reiterates Legend Biotech stock rating on pipeline progress - Investing.com
H.C. Wainwright reiterates Legend Biotech stock rating on pipeline progress By Investing.com - Investing.com India
HC Wainwright Boosts Earnings Estimates for Legend Biotech - MarketBeat
Legend Biotech (NASDAQ:LEGN) Trading 6.3% HigherStill a Buy? - MarketBeat
Q2 EPS Estimates for Legend Biotech Lowered by HC Wainwright - MarketBeat
H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales - Investing.com
H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales By Investing.com - Investing.com South Africa
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Legend Biotech (LEGN) Q2 2025 Earnings Transcript - The Globe and Mail
Legend Biotech Corporation Sponsored ADR $LEGN Shares Bought by SG Americas Securities LLC - MarketBeat
Legend Biotech (NASDAQ:LEGN) CEO Sells $87,138.72 in Stock - MarketBeat
Huang Ying, CEO of Legend Biotech, sells $87k in shares - Investing.com India
Recent Research Analysts’ Ratings Updates for Legend Biotech (LEGN) - Defense World
Virtus Biotech ETF Holdings - Quiver Quantitative
Hudson Bay Capital Management LP Has $7.17 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech Q1 EPS Estimate Decreased by HC Wainwright - MarketBeat
Braidwell LP Decreases Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
ArrowMark Colorado Holdings LLC Cuts Position in Axis Capital Holdings Limited $AXS - Defense World
UiPath (NYSE:PATH) Price Target Cut to $13.00 by Analysts at Wells Fargo & Company - Defense World
Capital International Investors Sells 140,873 Shares of Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
iShares MBS ETF $MBB Shares Acquired by Capital International Investors - Defense World
CLEAR Secure, Inc. (NYSE:YOU) Receives Average Recommendation of “Hold” from Analysts - Defense World
Royal Bank Of Canada Lowers Legend Biotech (NASDAQ:LEGN) Price Target to $62.00 - Defense World
Legend Biotech Plans to List in HK as Early as This Yr, Raising at Least US$300M: Wire - aastocks.com
RBC Capital lowers Legend Biotech stock price target on model updates By Investing.com - Investing.com South Africa
RBC Capital lowers Legend Biotech stock price target on model updates - Investing.com India
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales By Investing.com - Investing.com South Africa
Raymond James reiterates Legend Biotech stock rating on strong Q4 results - Investing.com India
Truist reiterates Buy on Legend Biotech stock, $70 target on capacity - Investing.com
Jefferies reiterates Legend Biotech stock rating on Carvykti sales - Investing.com India
Jefferies reiterates Legend Biotech stock rating on Carvykti sales By Investing.com - Investing.com South Africa
Legend Biotech Q4 Earnings Call Highlights - Yahoo Finance
Legend Biotech Q4 2025 slides: CARVYKTI turns profitable, $555M sales - Investing.com India
Earnings call transcript: Legend Biotech Q4 2025 shows strong growth By Investing.com - Investing.com India
Earnings call transcript: Legend Biotech Q4 2025 shows strong growth - Investing.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech Corp Adr (LEGN) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):